Petter Brodin

Petter Brodin

Professor/Specialistläkare
E-postadress: petter.brodin@ki.se
Telefon: +46852481396
Besöksadress: Biomedicum A5, Solnavägen 9, 17165 Solna
Postadress: K6 Kvinnors och barns hälsa, K6 Klinisk pediatrik Brodin, 171 77 Stockholm
Del av:

Om mig

  • Petter Brodin är född i Stockholm 1982. Han tog läkarexamen samt disputerade vid KI 2011. Efter postdoc 2012–2013 med Professor Mark M Davis,   HHMI, Stanford University, USA, återvände han till KI och SciLifeLab där han etablerade en första nationell infrastruktur för masscytometri, som han lett fram till 2023. Brodin blev docent 2018 och var avdelningschef för klinisk pediatrik 2019-2024.

    Som specialistläkare är han verksam vid Astrid Lindgrens barnsjukhus, barnreumatologiska kliniken, Karolinska Universitetssjukhuset sedan 2019. Brodins forskning har tilldelats ett flertal priser, bland annat KVA:s Göran Gustavsson Award 2020, Olle Söders pris, 2023, Oskar Medins pris, 2023. Han är invald fellow i Henry Kunckels samfund för humanimmunologi, EMBO young investigator sedan 2019, ledamot i Sverige unga akademi, 2019-2024.

    Petter Brodin har anställts som professor i pediatrisk immunologi vid Karolinska Institutet från 1 juli 2021.

Forskningsbeskrivning

  • Immunsystemets utveckling tidigt i livet hos nyfödda barn. Immunsystemets reglering vid hälsa och sjukdom och utveckling av nya immunomodulerande behandlingar. Teknikutveckling för at möjliggöra mer detaljerade studier av människors immunsystem. 

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Deutsche Forschungsgemeinschaft
    1 January 2024
    The Systemic environmental effects on neonatal Immune Development (SeenID) study is a highly innovative, ambitious, large-scale study to tackle a major global health concern: Neonatal immune system priming by the environment, predisposing to infections and immunopathologies later in life. After birth, the neonatal immune system must instantly cope with microbial colonization and environmental triggers and, at the same time, must provide immediate defense against invasive infections. While genetic variations cause specific immunodeficiencies and influence immune-related health and diseases later in life, it is mostly the environment that shapes the development and function of the human immune system early in extra-uterine life during a limited window of opportunity. Among the environmental factors contributing to the maturation of the immune system are the microbiome and exposure to potential pathogens, nutrition, which modulates the microbiome and immune reactions, as well as exposures to noxious agents, drugs, and standard-of-life environment. Episodes of immunological emergencies such as invasive infections are also influential. Here, we propose an approach based on a high-resolution, longitudinal analysis of >1000 neonates from highly distinctive, yet well-characterized environments over a two-year observational period. In the framework of two large intervention studies in rural Uganda and Kenya, we closely follow cohorts of neonates including assessment of health-associated data and sequential sampling of blood and stool. Recruitment is already successfully ongoing. The samples are locally stabilized and frozen, then shipped to Stockholm where they are analyzed side-by-side with age-matched samples from a Swedish cohort. This enables us to dissect specific environmental influences on the developing immune system. This study will provide a mechanistic understanding of factors involved in early immune programming and thus of early determinants contributing to infections and immunopathologies later in life.
  • Swedish Research Council
    1 January 2023 - 31 December 2027
    Purpose and aimImmune mediated diseases originate early in life, are linked with perturbed immune-microbe interactions and are increasingly prevalent. Our hypothesis is that environmental exposures at birth, and during the first months of life exert imprinting effects on developing immune cells, which determine an individual’s trajectory towards immunological health or disease. MethodsIn a birth cohort in Stockholm with 309 children, monitored for up to four years, we are analyzing longitudinal blood and stool samples, comparing children born at term or preterm, by vaginal or cesarean delivery and fed breastmilk or formula, whilst keeping track of many environmental factors such as the evolving gut microbiome, vaccines, and nutrients. We assess in vivo developmental outcomes
    atopy and serological responses to vaccines and compare children with different outcomes with respect to immunological features, metagenomes, and microbial metabolites. Furthermore, we aim to perform more in-depth in vitro experiments to investigate microbial metabolites for receptor binding, and functional modulation of epithelial cells and developing immune cells and the functional consequences thereof. ImportanceThese studies hold important potential by guiding future interventions in the form of pre/probiotics, metabolites, and nutritional supplements that hopefully can provide all children with a healthier start in life and promote immune-microbe mutualism and reduced risks of disease long term.
  • Swedish Research Council
    1 December 2022 - 30 November 2025
    Research problem and overall purpose
    COVID-19 has affected more than 2.4 million persons in Sweden. Some have a prolonged course after initial disease with debilitating symptoms
    Post-Acute COVID-19 Syndrome (PACS). The overall purpose of the research project is to characterise PACS patients regarding severity of residual symptoms, objectively analyse functional and patophysiological impairment in affected organs and explore underlying immunomechanistic causes.Relevance Investigating longterm PACS effects and increase the understanding of the various phenotypes and underlying mechanisms will generate effective ways to inform on novel treatment strategies and better protocols for clinical follow-up and design interventions for prevention. Data and methods In-depth phenotyping is generated from our post-COVID outpatient clinic with regular monitoring of previously hospitalized patients with initial severe Covid-19 and non-hospitalized PACS patients. A cohort of age and sex matched  COVID-19 patients without PACS  constitute a control group. We will perform systems-level analyses of blood immune cells, plasma proteins and bio-energetic measurements of blood cells in combination with whole genome sequencing from patients with severe PACS.Plan for project realization Abundant phenotypic patient data is now available for analysis as well as blood samples for immuno-mechanistic analysis. In depth studies of pulmonary, cardiovascular and other long term complications are ongoing.
  • Barncancerfonden
    1 January 2022 - 31 December 2022
  • Swedish Research Council
    1 December 2021 - 30 November 2024
  • Canadian Institutes of Health Research
    1 October 2021 - 30 September 2025
  • Swedish Research Council
    1 June 2021 - 31 May 2024
  • Swedish Research Council
    1 January 2021 - 31 December 2023
  • Swedish Research Council
    1 January 2021 - 31 December 2024
  • Swedish Heart-Lung Foundation
    1 January 2021 - 31 December 2021
  • Swedish Cancer Society
    1 January 2021
    The immune system has an impressive power to fight cancer cells and in recent years many new treatments have been added that help the immune system in its fight against cancer. Very few of these treatments are used on children, and children's immune systems are significantly different from adults. Research concerning the immune system in children with cancer is a neglected area, and in order to move forward with new treatment strategies, more information is now required on how current treatment affects the immune system and its function in children, and when and how a child's immune system is activated against cancer. The human immune system consists of a multitude of interacting white blood cells that regulate each other in a complex network. Therefore, despite good knowledge of individual cell types, we cannot predict the behavior of the immune system as a whole. New technology now allows us to study the immune system as a whole with all its white blood cells. This can be done with repeated blood tests. Here we use such new methods in children with solid tumors, including brain tumors and lymphoma. However, leukemias are not included. We study how the immune system is affected by current treatments and try to predict which children will suffer complications and which will not. We hope that this new knowledge about the immune system in children with cancer will lead to more children being able to be helped by immunotherapy and to be cured, that we will be able to better tailor our treatment, not only according to the characteristics of the tumor but also according to the child's immune system, so that this may work in repelling cancer cells. We also hope that we will get better at finding the children with the greatest risk of complications due to reduced immune function such as infections and that we will be able to predict such risks earlier.
  • Swedish Research Council
    1 January 2020 - 31 December 2023
  • Knut and Alice Wallenberg Foundation
    1 January 2020 - 1 January 2025
  • Swedish Research Council
    1 January 2019 - 31 December 2021
  • Swedish Research Council
    1 December 2018 - 30 November 2023
  • ISAC - Immune System Against Cancer in Children: A New Platform for Increased Knowledge of the Immune System in Children with Cancer, Aiming to Accelerate the Introduction of Immunotherapy
    Swedish Cancer Society
    1 January 2018
    Survival for children affected by cancer has improved significantly but cancer is still one of the most common causes of death in children in Sweden. Medications aimed at improving the immune system's own ability to kill tumor cells have made great progress in recent years and show great potential but such treatments have not been used for children with solid tumors. The immune system of children and adult patients differs and an important first step towards the introduction of new immunological treatments in children is to increase our knowledge of how tumors and prevailing treatment protocols affect children's immune systems. The human immune system consists of many interacting cell types that regulate each other in a complicated network. Despite good knowledge of individual cell types, we cannot therefore predict the function of the immune system as a whole today. New technology offers new opportunities for extensive analysis of all the cells and proteins that make up human immune system and its function. We now want to use such methods to study the immune system in children with cancer, how its composition and function are affected by the disease and the treatment they are undergoing. If we are successful, we hope to see how the immune systems of children with cancer respond to different tumors and compare such responses in patients who survive to those who do not, something that would open to new treatments where the immune system's function is directed towards better attacking cancer cells in all children. We also believe that such analyzes can help us understand how and why some children suffer from side effects to their treatment, side effects that often involve the immune system.
  • The maturation of a well-balanced immune system determines the prognosis for patients with leukemia who undergo stem cell transplantation.
    Swedish Cancer Society
    1 January 2017
    Today, stem cell transplantation is an effective treatment for patients with leukemia but too many still suffer from severe complications such as infections, graft-versus host reaction and recurrence of leukemia. We do not know today what is required for the new immune system when it grows out of donated stem cells in order for the patient to be cured. With the help of the latest method for cell analysis, mass cytometry, we now want to study the immune systems of these patients to try to understand what distinguishes patients who are cured without complications from those who do not. Our hypothesis is that complications in patients can be explained by the fact that the immune system develops with an imbalance between different cell populations after transplantation. Thus, some cell populations can dominate the system and its function as a whole is weakened. We now want to investigate this idea If our idea of imbalance between cell types as an explanation for poor immunological function is correct, this opens up for both new possibilities for detecting threatening complications and earlier treatment of these. Thus, we hope to improve survival for patients with leukemia who undergo stem cell transplantation
  • The maturation of a well-balanced immune system determines the prognosis for patients with leukemia who undergo stem cell transplantation.
    Swedish Cancer Society
    1 January 2016
    Today, stem cell transplantation is an effective treatment for patients with leukemia but too many still suffer from severe complications such as infections, graft-versus host reaction and recurrence of leukemia. We do not know today what is required for the new immune system when it grows out of donated stem cells in order for the patient to be cured. With the help of the latest method for cell analysis, mass cytometry, we now want to study the immune systems of these patients to try to understand what distinguishes patients who are cured without complications from those who do not. Our hypothesis is that complications in patients can be explained by the fact that the immune system develops with an imbalance between different cell populations after transplantation. Thus, some cell populations can dominate the system and its function as a whole is weakened. We now want to investigate this idea If our idea of imbalance between cell types as an explanation for poor immunological function is correct, this opens up for both new possibilities for detecting threatening complications and earlier treatment of these. Thus, we hope to improve survival for patients with leukemia who undergo stem cell transplantation
  • Swedish Research Council
    1 January 2016 - 31 December 2019
  • The maturation of a well-balanced immune system determines the prognosis for patients with leukemia who undergo stem cell transplantation.
    Swedish Cancer Society
    1 January 2015
    Today, stem cell transplantation is an effective treatment for patients with leukemia but too many still suffer from severe complications such as infections, graft-versus host reaction and recurrence of leukemia. We do not know today what is required for the new immune system when it grows out of donated stem cells in order for the patient to be cured. With the help of the latest method for cell analysis, mass cytometry, we now want to study the immune systems of these patients to try to understand what distinguishes patients who are cured without complications from those who do not. Our hypothesis is that complications in patients can be explained by the fact that the immune system develops with an imbalance between different cell populations after transplantation. Thus, some cell populations can dominate the system and its function as a whole is weakened. We now want to investigate this idea If our idea of imbalance between cell types as an explanation for poor immunological function is correct, this opens up for both new possibilities for detecting threatening complications and earlier treatment of these. Thus, we hope to improve survival for patients with leukemia who undergo stem cell transplantation

Anställningar

  • Professor/Specialistläkare, Kvinnors och barns hälsa, Karolinska Institutet, 2021-

Examina och utbildning

  • Docent, Immunologi, Karolinska Institutet, 2018
  • Medicine Doktorsexamen, Institutionen för mikrobiologi, tumör- och cellbiologi, Karolinska Institutet, 2011
  • Läkarexamen, Karolinska Institutet, 2010

Priser och utmärkelser

  • Wallenberg Scholar, Knut and Alice Wallenberg Foundation, 2024
  • VR Consolidator award, Swedish Research Council, 2022
  • SSMF Consolidator award, Swedish Society for Medical Research, 2022
  • Göran Gustavsson award, Royal Swedish Academy of Sciences, 2019
  • EMBO Young Investigator, European Molecular Biology Organization, 2019
  • Wallenberg Academy Fellow, Knut and Alice Wallenberg Foundation, 2019
  • Jonas Söderquist Scholarship, 2019
  • Member, Young Academy of Sweden, 2019
  • The Sven and Ebba-Christina Hagberg Prize, By the Sven and Ebba-Christina Hagberg foundation, 2018
  • Wallenberg Clinical Fellow, Marianne and Marcus Wallenberg Foundation, 2017
  • ERC starting grant, European Research Council, 2015
  • VR young researcher grant, Swedish Research Council, 2015
  • SSMF young researcher grant, Swedish Society for Medical Research, 2014
  • Wenner-Gren Fellow, 2012
  • Prins Bertil's award, Sweden America Foundation, 2012
  • Doktorsexamen, 2009

Gästforskning och resestipendier

  • Postdoc, Stanford University School of Medicine, 2012-2013

Nyheter från KI

Kalenderhändelser från KI